Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more
Hanall Biopharma (009420) - Net Assets
Latest net assets as of September 2025: ₩157.65 Billion KRW
Based on the latest financial reports, Hanall Biopharma (009420) has net assets worth ₩157.65 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩201.82 Billion) and total liabilities (₩44.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩157.65 Billion |
| % of Total Assets | 78.12% |
| Annual Growth Rate | 9.67% |
| 5-Year Change | -7.13% |
| 10-Year Change | 76.81% |
| Growth Volatility | 33.99 |
Hanall Biopharma - Net Assets Trend (2011–2024)
This chart illustrates how Hanall Biopharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hanall Biopharma (2011–2024)
The table below shows the annual net assets of Hanall Biopharma from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩168.35 Billion | -9.59% |
| 2023-12-31 | ₩186.22 Billion | +10.68% |
| 2022-12-31 | ₩168.26 Billion | +2.91% |
| 2021-12-31 | ₩163.49 Billion | -9.81% |
| 2020-12-31 | ₩181.27 Billion | +29.10% |
| 2019-12-31 | ₩140.42 Billion | +20.10% |
| 2018-12-31 | ₩116.92 Billion | +5.14% |
| 2017-12-31 | ₩111.20 Billion | +6.55% |
| 2016-12-31 | ₩104.36 Billion | +9.60% |
| 2015-12-31 | ₩95.22 Billion | +107.85% |
| 2014-12-31 | ₩45.81 Billion | -23.17% |
| 2013-12-31 | ₩59.63 Billion | -24.21% |
| 2012-12-31 | ₩78.67 Billion | +55.16% |
| 2011-12-31 | ₩50.70 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hanall Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2732.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩26.49 Billion | 15.74% |
| Other Components | ₩141.86 Billion | 84.26% |
| Total Equity | ₩168.35 Billion | 100.00% |
Hanall Biopharma Competitors by Market Cap
The table below lists competitors of Hanall Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enovis Corp
NYSE:ENOV
|
$1.26 Billion |
|
HOEGH AUTOLINERS NK 2120
F:V02
|
$1.26 Billion |
|
Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
SHE:301093
|
$1.26 Billion |
|
Loma Negra Compañía Industrial Argentina Sociedad Anónima
F:8LN
|
$1.26 Billion |
|
NGL Energy Partners LP
NYSE:NGL
|
$1.26 Billion |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
$1.26 Billion |
|
Primaris Real Estate Investment Trust
PINK:PMREF
|
$1.26 Billion |
|
Stadler Rail AG
PINK:SRAIF
|
$1.26 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hanall Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 186,218,369,830 to 168,351,403,330, a change of -17,866,966,500 (-9.6%).
- Net loss of 1,804,843,470 reduced equity.
- New share issuances of 1,701,767,770 increased equity.
- Other factors decreased equity by 17,763,890,800.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-1.80 Billion | -1.07% |
| Share Issuances | ₩1.70 Billion | +1.01% |
| Other Changes | ₩-17.76 Billion | -10.55% |
| Total Change | ₩- | -9.59% |
Book Value vs Market Value Analysis
This analysis compares Hanall Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.67x to 16.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩2172.82 | ₩53600.00 | x |
| 2018-12-31 | ₩2284.59 | ₩53600.00 | x |
| 2019-12-31 | ₩2743.77 | ₩53600.00 | x |
| 2020-12-31 | ₩3541.94 | ₩53600.00 | x |
| 2021-12-31 | ₩3192.82 | ₩53600.00 | x |
| 2022-12-31 | ₩3319.29 | ₩53600.00 | x |
| 2023-12-31 | ₩3673.44 | ₩53600.00 | x |
| 2024-12-31 | ₩3319.87 | ₩53600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hanall Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.30%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.26x
- Recent ROE (-1.07%) is above the historical average (-2.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -36.06% | -28.96% | 0.76x | 1.64x | ₩-27.46 Billion |
| 2014 | -27.63% | -15.65% | 0.93x | 1.90x | ₩-17.24 Billion |
| 2015 | -7.43% | -8.84% | 0.68x | 1.23x | ₩-16.60 Billion |
| 2016 | 1.94% | 2.44% | 0.66x | 1.20x | ₩-8.41 Billion |
| 2017 | 5.23% | 6.90% | 0.50x | 1.52x | ₩-5.31 Billion |
| 2018 | 2.82% | 3.59% | 0.57x | 1.39x | ₩-8.39 Billion |
| 2019 | 13.66% | 17.68% | 0.57x | 1.36x | ₩5.13 Billion |
| 2020 | 10.90% | 22.31% | 0.40x | 1.21x | ₩1.64 Billion |
| 2021 | 5.44% | 8.76% | 0.51x | 1.21x | ₩-7.45 Billion |
| 2022 | 0.15% | 0.23% | 0.52x | 1.27x | ₩-16.57 Billion |
| 2023 | 1.88% | 2.60% | 0.56x | 1.29x | ₩-15.11 Billion |
| 2024 | -1.07% | -1.30% | 0.65x | 1.26x | ₩-18.64 Billion |
Industry Comparison
This section compares Hanall Biopharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $472,965,132,317
- Average return on equity (ROE) among peers: 3.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hanall Biopharma (009420) | ₩157.65 Billion | -36.06% | 0.28x | $1.26 Billion |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $76.07 Million |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $3.71 Billion |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $29.69 Million |
| Ildong Holdings Co Ltd (000230) | $310.17 Billion | 8.80% | 0.65x | $48.77 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $103.58 Million |
| Donga Socio Holdings (000640) | $1.03 Trillion | 5.64% | 0.91x | $204.37 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $278.79 Million |
| JW Pharmaceutical Corp (001065) | $276.31 Billion | -3.96% | 1.36x | $246.19 Million |
| Samsung Pharm (001360) | $46.24 Billion | -2.15% | 1.82x | $64.85 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $165.68 Billion | 10.17% | 0.83x | $27.46 Million |